ExplainedHealth
Cancer drug trade margin cap explained: why MRPs of 137 medicines fall from November 9
Chemists and hospitals must charge new, lower prices for 137 anti-cancer drugs from Monday. What a trade margin is, how a 30% cap pulls the MRP down, and what patients should check.
The short answer
A trade margin is the gap between what a manufacturer sells a medicine for and the maximum retail price (MRP) printed on the pack, and it covers wholesalers, hospitals and chemists. On October 17, 2026, the National Pharmaceutical Pricing Authority capped that margin at 30% of the MRP for 137 non-scheduled anti-cancer drugs, under Paragraph 19 of the Drugs (Prices Control) Order, 2013. The revised MRPs apply from Monday, November 9, and the Centre expects prices to fall by up to 70%, depending on how each product was priced before.
What is a trade margin?
It is the slice of an MRP that goes to the supply chain, not the maker. A medicine travels from the manufacturer to a distributor, then to a hospital or chemist, and each step adds a margin. The MRP is the highest price a patient can be charged. Because hospitals tend to buy from the manufacturers who offer the biggest margins, the Department of Pharmaceuticals told the Supreme Court that margins on cancer medicines range from 170% to more than 700%.
For drugs that already have a ceiling price under the 2013 order, the price includes a 16% retailer margin. The 137 drugs here had no such ceiling, so the MRP was largely left to the company, and the gap between what hospitals paid and what patients were charged could be wide.
What has the government done?
It has capped the trade margin at 30% of the MRP for 137 anti-cancer drugs. The National Pharmaceutical Pricing Authority (NPPA) issued the gazette notification on October 17, 2026. It used Paragraph 19 of the Drugs (Prices Control) Order, 2013, the clause the authority invokes for trade margin rationalisation.
The drugs are non-scheduled, meaning they do not have a fixed ceiling price under the order. An expert committee under the Directorate General of Health Services, with oncologists, hospital experts and officials, recommended the list, and it will be updated from time to time.
How did it get here?
A pilot in 2019 and a court hearing in October. In 2019 the NPPA capped margins at 30% on 42 anti-cancer medicines. According to the government this reduced the MRPs of 526 brands by up to 90%. In 2026 the Centre told the Supreme Court on October 12 that the NPPA had decided on October 8 to extend the idea to most approved cancer drugs, and the bench asked why it stopped at cancer.
From pilot to price change
- 2019Margins capped at 30% on 42 anti-cancer drugs
- Oct 8, 2026NPPA meeting decides to extend the cap
- Oct 12, 2026Centre tells the Supreme Court about the 30% cap
- Oct 17, 2026Gazette notification covers 137 drugs
- Nov 9, 2026Revised MRPs take effect
How far will prices fall?
By up to 70%, says the Ministry of Chemicals and Fertilizers, but it varies by product. The NPPA has since published lists of company-reported new MRPs: 543 entries, then 643 entries as of October 28. These are brands, strengths and pack sizes, not 643 drugs.
RPG Life Sciences’ Palbopro (palbociclib 125 mg, 21 capsules) falls about 93%, from ₹40,421.33 to ₹2,720. Cipla’s Armotraz (anastrozole 1 mg) goes from ₹784.71 to ₹146.78. Some well-known brands show no change: Keytruda (pembrolizumab 100 mg) stays at ₹2,16,500, with Tagrisso and Imfinzi also unchanged in the latest list.
Who must do what from Monday?
Retailers and hospitals must charge the revised prices and display them. Hospitals must also put the new rates on their websites. Manufacturers must tell the NPPA of their revised prices within seven days of the notification, publish price lists and send them to retailers and hospitals. They must also keep production and supply at current levels, and State Drug Controllers will enforce compliance.
What should patients check?
The NPPA website or the Pharma Sahi Daam app. Patients can look up the revised price of a drug there. A lower printed MRP does not always mean an equal saving at the counter, particularly where a hospital or chemist was already selling below the old MRP.
Why not every medicine?
The government argues one margin would not suit all products. The bench noted a cardiac stent with a price to retailer of ₹5,000 and an MRP of ₹25,000. The Centre replied that distribution costs differ by product and place, and that cheap drugs, cold-chain products and remote areas may need higher margins. The affidavit also said hospital consumables carry margins of 100% to over 1,000%, and the government told the court that heavy intervention could hurt availability. Whether the idea spreads beyond cancer drugs is a question the court has kept open. These figures are as of November 2026.